📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol. (2023)

First Author: McClure M

Attributed to: A mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.17863/cam.95971

Publication URI: https://www.repository.cam.ac.uk/handle/1810/348540

Type: Journal Article/Review